Stock Short Interest Filing: Boston Scientific Corporation (NYSE:BSX) Sellers Increased By 9.41% Their Shorts

November 28, 2016 - By Louis Casey   ·   0 Comments

Stock Short Interest Filing: Boston Scientific Corporation (NYSE:BSX) Sellers Increased By 9.41% Their Shorts

The stock of Boston Scientific Corporation (NYSE:BSX) registered an increase of 9.41% in short interest. BSX’s total short interest was 18.81 million shares in November as published by FINRA. Its up 9.41% from 17.19M shares, reported previously. With 10.42M shares average volume, it will take short sellers 2 days to cover their BSX’s short positions. The short interest to Boston Scientific Corporation’s float is 1.5%. The stock increased 0.81% or $0.17 on November 25, hitting $21.15. Boston Scientific Corporation (NYSE:BSX) has risen 7.14% since April 25, 2016 and is uptrending. It has outperformed by 1.13% the S&P500.

Boston Scientific Corporation is a developer, maker and marketer of medical devices that are used in a range of interventional medical specialties. The company has a market cap of $29.03 billion. The Firm offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions , Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation. It has a 370.99 P/E ratio. It operates in three divisions: Cardiovascular, Rhythm Management and MedSurg.

Insitutional Activity: The institutional sentiment decreased to 1.12 in Q2 2016. Its down 0.04, from 1.16 in 2016Q1. The ratio fall, as 25 funds sold all Boston Scientific Corporation shares owned while 168 reduced positions. 63 funds bought stakes while 160 increased positions. They now own 1.23 billion shares or 2.15% less from 1.26 billion shares in 2016Q1.
Rwc Asset Mngmt Llp reported 300 shares or 0% of all its holdings. Blair William Il, a Illinois-based fund reported 40,122 shares. Argent Cap Mgmt Ltd Llc holds 2.3% of its portfolio in Boston Scientific Corporation (NYSE:BSX) for 2.20M shares. The Illinois-based Piershale Fincl Gru has invested 0% in Boston Scientific Corporation (NYSE:BSX). Capital Ww holds 0.52% of its portfolio in Boston Scientific Corporation (NYSE:BSX) for 81.94M shares. Everence Capital Mgmt last reported 0.27% of its portfolio in the stock. Natl Pension Serv accumulated 0.19% or 899,607 shares. Moreover, Tudor Invest Et Al has 0.02% invested in Boston Scientific Corporation (NYSE:BSX) for 33,994 shares. Aperio Gru Ltd Liability Corp accumulated 0.07% or 404,270 shares. Hightower Advsr holds 0% of its portfolio in Boston Scientific Corporation (NYSE:BSX) for 16,223 shares. Pacad Ltd has 76,456 shares for 0.25% of their US portfolio. Shell Asset Mngmt holds 0.1% or 175,658 shares in its portfolio. Profund Advsrs Ltd Liability Corporation accumulated 56,447 shares or 0.06% of the stock. Keybank National Association Oh owns 25,720 shares or 0% of their US portfolio. The Germany-based Dekabank Deutsche Girozentrale has invested 0.1% in Boston Scientific Corporation (NYSE:BSX).

Insider Transactions: Since June 1, 2016, the stock had 0 buys, and 8 sales for $5.11 million net activity. Pratt Timothy A. sold $586,956 worth of Boston Scientific Corporation (NYSE:BSX) on Monday, August 1. Shares for $841,050 were sold by Phalen Michael P. on Wednesday, July 20. Mahoney Michael F had sold 100,000 shares worth $2.27M. $59,594 worth of Boston Scientific Corporation (NYSE:BSX) was sold by Pierce David A. Sorenson John Bradley sold $59,750 worth of stock. On Wednesday, July 20 the insider Ballinger Kevin J. sold $1.88 million.

Boston Scientific Corporation (NYSE:BSX) Ratings Coverage

Out of 22 analysts covering Boston Scientific Corporation (NYSE:BSX), 17 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 77% are positive. Boston Scientific Corporation has been the topic of 29 analyst reports since July 27, 2015 according to StockzIntelligence Inc. On Thursday, September 1 the stock rating was upgraded by Argus Research to “Buy”. The stock has “Hold” rating given by Jefferies on Friday, July 29. The stock of Boston Scientific Corporation (NYSE:BSX) has “Neutral” rating given on Monday, May 23 by BTIG Research. On Thursday, November 12 the stock rating was initiated by Citigroup with “Buy”. Wedbush maintained the stock with “Neutral” rating in Thursday, April 28 report. As per Thursday, March 17, the company rating was initiated by Nomura. The firm earned “Neutral” rating on Thursday, August 27 by Goldman Sachs. The stock of Boston Scientific Corporation (NYSE:BSX) has “Buy” rating given on Monday, September 28 by Needham. Guggenheim initiated Boston Scientific Corporation (NYSE:BSX) on Thursday, June 9 with “Buy” rating. Citigroup maintained the stock with “Buy” rating in Thursday, October 6 report.

BSX Company Profile

Boston Scientific Corporation, incorporated on June 22, 1979, is a developer, maker and marketer of medical devices that are used in a range of interventional medical specialties. The Firm offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation. The Firm operates through three divisions: Cardiovascular, Rhythm Management and MedSurg. The Company’s Cardiovascular segment consists of Interventional Cardiology and PI businesses. The Company’s Rhythm Management segment consists of CRM and EP businesses. The Company’s MedSurg segment consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses.

More important recent Boston Scientific Corporation (NYSE:BSX) news were published by: Prnewswire.com which released: “Boston Scientific To Participate In Citi 2016 Global Healthcare Conference” on November 23, 2016, also Prnewswire.com published article titled: “Boston Scientific Acquires Resectrâ„¢ Tissue Resection Device from Distal …”, Prnewswire.com published: “Boston Scientific To Participate In Piper Jaffray 2016 Healthcare Conference” on November 16, 2016. More interesting news about Boston Scientific Corporation (NYSE:BSX) was released by: Streetinsider.com and their article: “Boston Scientific (BSX) Announces C Losing of $210 EndoChoice (GI) Acquisition” with publication date: November 22, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Louis Casey


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>